Abstract:Objective To investigate the performance of DWI in the prediction of the response of gastrointestinal stromal tumor (GIST) to targeted therapy.Methods Twenty nine consecutive patients with unresectable GIST confirmed by pathology were enrolled in this prospective study.All patients were treated by imatinib mesylate single drug,and had at least one targeted lesion with longest diameter＞ 1 cm.MRI examinations were performed prior to and 2 weeks and 3 months afollowing treatment.The ADC of the whole lesion (ADCentire) and obviously high signal area on DWI (ADCmin) and the longest diameter (LD) on T2WIs were measured.The early percentage changes of the quantitative indicators (％ Δ LD,％ Δ ADCmin and ％ ΔADCentire) were calculated.All patients were divided into good response (GoodR) and poor response (PoorR) groups according to the combined response assessment criteria.The pre-therapy values and early percentage changes (％Δ) of the above quantitative parameters were compared using t test or Mann-Whitney U test.Receiver operating characteristic (ROC) curves were employed to compare the performance of the above quantitative parameters in the discrimination of response groups.Results A total of 82 lesions in 29 patients were included in the study.There were 57 lesions of GoodR and 25 lesions of PoorR.The pre-therapy baseline ADCmin and ADC in GoodR group were both lower than PoorR group [ADCmin:(0.90± 0.27) × 10-3 mm2/s vs.(1.15± 0.29) × 10-3 mm2/s,t=3.673,P＜0.01 ;ADCentire:(1.06 ± 0.26) × 10-3mm2/s vs.(1.31 ± 0.32) × 103mm2/s,t=3.698,P＜0.01].No statistical difference in baseline LD was displayed (P＞0.05).The ％ ΔADC ％ΔADC and ％ΔLD all had statistical difference between GoodR and PoorR groups(％ΔADCmin:48％ vs.3％,Z=-5.310,P＜0.01;％ΔADCentire:45％ vs.2％,Z=-5.768,P＜0.01;％ΔLD:-6％ vs.-1％,Z=-2.752,P＜0.01).Through ROC curves,the AUCs for pre-therapy ADCmin,ADCentire and LD were 0.735,0.721 and 0.503,respectively; and AUCs for ％ΔADCmin,％ΔADCentire and ％ΔLD after two weeks of therapy were 0.859,0.877 and 0.694,respectively,in the differentiation of responses.Using ％ ΔADCmin ≥ 13％ to predict GoodR,the sensitivity was 0.842 and specificity 0.760; Using ％ΔADCentire ≥ 22％ to predict GoodR,the sensitivity was 0.862 and specificity 0.800.Conclusions The percentage changes of the ADC after two weeks of therapy outperform the longest diameter and pre-therapy baseline ADC in the response predictionof GIST to targeted therapy.It is more effective of ADCentire than ADCmin values in the respo nse prediction.

The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation

The Therapeutic Response Of Gastrointestinal Stromal Tumors To Imatinib Treatment Assessed By Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging With Histopathological Correlation (Vol 11, E0167720, 2016)

Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients.

Chemotherapy Response Evaluation in A Mouse Model of Gastric Cancer Using Intravoxel Incoherent Motion Diffusion-Weighted Mri and Histopathology

MR diffusion weighted imaging in the prediction of the response of unresectable gastrointestinal stromal tumor to targeted therapy

Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Early Evaluation of Imatinib in Treatment of Gastrointestinal Stromal Tumor Using CT Imaging

Could Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging Be Feasible and Beneficial to the Evaluation of Gastrointestinal Tumors Histopathology and the Therapeutic Response?

Comparison of intravoxel incoherent motion imaging, diffusion kurtosis imaging, and conventional DWI in predicting the chemotherapeutic response of colorectal liver metastases

Evaluation of Effects of TGF‐β1 Inhibition on Gastric Cancer in Nude Mice by Diffusion Kurtosis Imaging and In‐Line X‐ray Phase Contrast Imaging with Sequential Histology

Diffusion‐weighted MRI Monitoring of Pancreatic Cancer Response to Radiofrequency Heat‐enhanced Intratumor Chemotherapy

Performing IVIM-DWI Using the Multifunctional Nanosystem for the Evaluation of the Antitumor Microcirculation Changes

Sensitive Metabolites and Single Nuclear Polymorphisms of OCT1 on Imatinib Meyslate in Patients with Gastrointestinal Stromal Tumors (GISTs)

Imaging Evaluation of Targeted Therapy for Gastrointestinal Stromal Tumor

Clinical Analysis of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor

Early Changes in Intravoxel Incoherent Motion MRI Parameters Can Potentially Predict Response to Chemoradiotherapy in Rectal Cancer: an Animal Study.

Intravoxel Incoherent Motion Diffusion‐Weighted Imaging for Predicting and Monitoring the Response of Anti‐Angiogenic Treatment in the Orthotopic Nude Mouse Model of Lung Adenocarcinoma

Non‐Gaussian Diffusion Imaging with a Fractional Order Calculus Model to Predict Response of Gastrointestinal Stromal Tumor to Second‐line Sunitinib Therapy

Use of Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) to Predict Early Response to Anti-Tumor Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): a Comparison of Intravoxel Incoherent Motion-Derived Parameters and Apparent Diffusion Coefficient

Advancing gastrointestinal stromal tumor management: The role of imagomics features in precision risk assessment